Blue test tubes arranged in a line, disappearing into the background

Drug news

Arcapta Neohaler (Novartis) is launched in USA for COPD

Read time: 1 mins

Last updated:22nd Mar 2012

Published:22nd Mar 2012

Source: Pharmawand

Novartis has launched its once-daily long-acting beta2 agonist Arcapta Neohaler (indacaterol inhalation powder) in the USA following its approval for chronic obstructive pulmonary disease by the FDA in July 2011. Indacaterol is already available in more than 30 countries following its first approval in the EU in November 2009 as Onbrez Breezhaler. The drug is approved in a total of 80 markets and further launches are due this year.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves perioperative treatment of neoadjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant single-agent Opdivo for resectable NSCLC

Bristol Myers Squibb announced that the FDA approved Opdivo (nivolumab) for the treatment of adult patients with resectable (tumors greater than T4 cm or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent Opdivo as adjuvant treatment after surgery – otherwise referred to as perioperative therapy, which is used before and after surgery.

3 mins

Drug news

NICE (UK) Positive for latanoprost–netarsudil combination to treat primary open-angle glaucoma or ocular hypertension

Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not reduced IOP enough

1 min

Drug news

Recordati acquires Enjaymo ( sutimlimab) from Sanofi

Recordati announces an agreement with Sanofi to acquire the global rights to Enjaymo (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.

1 min

See all news